Skip to main navigation Skip to search Skip to main content

ATP13A2 variants in early-onset Parkinson's disease patients and controls

Ana Djarmati, Johann Hagenah, Kathrin Reetz, Susen Winkler, Maria Isabel Behrens, Heike Pawlack, Katja Lohmann, Alfredo Ramirez, Vera Tadić, Norbert Brüggemann, Daniela Berg, Hartwig R. Siebner, Anthony E. Lang, Peter P. Pramstaller, Ferdinand Binkofski, Vladimir S. Kostić, Jens Volkmann, Thomas Gasser, Christine Klein*

*Corresponding author for this work

Abstract

Four genes responsible for recessively inherited forms of Parkinson's disease (PD) have been identified, including the recently discovered ATP13A2 (PARK9) gene. Our objective was to investigate the role of this gene in a large cohort of PD patients and controls. We extensively screened all 29 exons of the ATP13A2 coding region in 112 patients with early-onset PD (EOPD; <40 years) of mostly European ethnic origin and of 55 controls. We identified four carriers (3.6%) of novel single heterozygous ATP13A2 missense changes that were absent in controls. Interestingly, the carrier of one of these variants also harbored two mutations in the Parkin gene. None of the carriers had atypical features previously described in patients with two mutated ATP13A2 alleles (Kufor-Rakeb syndrome). Our data suggest that two mutated ATP13A2 alleles are not a common cause of PD. Although heterozygous variants are present in a considerable number of patients, they are - based on this relatively small sample - not significantly more frequent in patients compared to controls.

Original languageEnglish
JournalMovement Disorders
Volume24
Issue number14
Pages (from-to)2104-2111
Number of pages8
ISSN0885-3185
DOIs
Publication statusPublished - 30.10.2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 10 - Reduced Inequalities
    SDG 10 Reduced Inequalities

Fingerprint

Dive into the research topics of 'ATP13A2 variants in early-onset Parkinson's disease patients and controls'. Together they form a unique fingerprint.

Cite this